CTRI/2012/08/002883
Completed
未知
Double blind, randomized placebo controlled study to evaluate the safety and efficacy of IND02 as an adjuvant in breast cancer chemotherapy
Indus Biotech Private Limited0 sites34 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Indus Biotech Private Limited
- Enrollment
- 34
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Female patients between 18 years and 70 years of age.
- •Patients with histologically or cytologically confirmed primary carcinoma of the breast by using core biopsy, needle biopsy or fine\-needle aspiration cytology.
- •Patients who have undergone mastectomy and with indications for Chemotherapy.
- •Patients with Leucocyte count more than 4000/mm³.
- •Patients with Platelet count more than 100,000/mm³.
- •Patients with Hemoglobin more than 10\.0 g/dL.
- •Patients who are willing and able to comply with the study procedures and provide written informed consent to participate in the study.
Exclusion Criteria
- •Patients who have received prior Chemotherapy or hormonal therapy for the treatment of breast cancer within the last 6 months.
- •Patients with existing Mucositis or oral and throat pain condition prior to starting Chemotherapy.
- •Patient who have already shaved the scalp hair before receiving Chemotherapy.
- •Patients known to have hypersensitivity to the study medication, its excipients, its analogs, or any of the components of herbs.
- •Patients diagnosed with active sero\-positive Acquired Immunodeficiency Syndrome (AIDS) or Hepatitis B/C.
- •Pre\-menopausal female patients who are pregnant, lactating or of child bearing potential and not on contraceptives.
- •Patients with altered mental status precluding understanding of the informed consent process and/or completion of the necessary assessments.
- •Patients with other severe diseases including abnormal cardiac conditions, hepatic or renal disorder, uncontrolled diabetes or other medical conditions that is likely to interfere with the study in the investigatorâ??s judgment.
- •Patients who have participated in other cancer trials in the past 30 days.
- •Patients who, in the investigatorâ??s clinical judgment, are not suitable for this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Double blind, placebo controlled randomized study of the effects of co-administering testosterone with PDE V inhibitor in ED patients non responders to PDE V inhibitors alone - TADTESTEUCTR2005-000852-34-DESELARL du Docteur Jacques BUVAT430
Active, not recruiting
Not Applicable
Double blind, placebo controlled randomized study of the effects of co-administering testosterone with PDE V inhibitor in ED patients non responders to PDE V inhibitors alone - TADTESTErectile dysfunctionClassification code 10061461EUCTR2005-000852-34-ATSELARL du Docteur Jacques Buvat430
Active, not recruiting
Phase 1
Double blind, placebo controlled randomized study of the effects of co-administering testosterone with PDE V inhibitor in ED patients non responders to PDE V inhibitors alone - TADTESTErectile dysfunctionClassification code 10061461EUCTR2005-000852-34-FICETPARP430
Active, not recruiting
Not Applicable
Double-blind, randomized placebo controlled study on the effect from cortisone treatment of acute loss of vestibular or balance function of the inner ear - function, subjective well-being and stressEUCTR2014-005484-32-SEund University
Active, not recruiting
Phase 1
Double-blind, placebo controlled randomized study of the effects of co-administering testosterone with PDE V inhibitor in ED patients non responders to PDE V inhibitors alone. - TADTESTErectile dysfunctionClassification code 10061461EUCTR2005-000852-34-GBSELARL du Dr Jacques BUVAT430